Strides Shasun receives tentative nod from USFDA for HIV drug Efavirenz

May 27, 2016 12:16 IST

Strides ShasunStrides Shasun on 26 May 2016 announced that it has received tentative approval from the U.S. Food and Drug Administration (USFDA) for Efavirenz tablets USP, 600 mg.

The final approval will be received after patent expiry in August 2018. The company will manufacture the product at its oral dosage facility in Bengaluru.

About Efavirenz

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI).

It is used as part of Highly Active Antiretroviral Therapy (HAART) for the treatment of a Human Immunodeficiency Virus (HIV) type 1.

It is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to reduce the risk of HIV infection in people exposed to a significant risk.

It was discovered at Merck Research Laboratories.

It is on the WHO Model List of Essential Medicines, the most important medication needed in a basic health system.

About Strides Shasun

Strides Arcolab is an Indian pharmaceutical company, headquartered at Bangalore in southern India.

The company manufactures pharmaceutical products, over-the-counter drugs and nutraceuticals.

The company has 15 manufacturing sites in six countries and marketing presence in 50 countries.

The company's stock trades on the Bombay Stock Exchange and on the National Stock Exchange of India.

Strides Arcolab changed name to Strides Shasun Ltd after an amalgamation of Shasun Pharmaceuticals with Strides Arcolab.

Arun Kumar is the founder and Group CEO, and has been on the Board as Managing Director since its inception.

Now get latest Current Affairs on mobile, Download # 1  Current Affairs App

Is this article important for exams ? Yes4 People Agreed
Read more Current Affairs on: Strides Shasun , Efavirenz , HIV , HAART , Human Immunodeficiency Virus

DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.

Latest Videos

Register to get FREE updates

    All Fields Mandatory
  • (Ex:9123456789)
  • Please Select Your Interest
  • Please specify

  • ajax-loader
  • A verifcation code has been sent to
    your mobile number

    Please enter the verification code below

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK